We compared the effect of dasatinib on CTGF expression to that of a panel of TKIs, including lapatinib, erlotinib, sorafenib, and crizotinib, which have been investigated in clinical studies for GC treatment [40–43]. Here, CCN2 is linked to gastric cancer.